This company listing is no longer active
0RAQ Stock Overview
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Karo Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr60.53 |
| 52 Week High | kr62.00 |
| 52 Week Low | kr49.25 |
| Beta | 0.10 |
| 1 Month Change | 0.21% |
| 3 Month Change | 0.88% |
| 1 Year Change | 4.54% |
| 3 Year Change | 57.63% |
| 5 Year Change | 55.16% |
| Change since IPO | -49.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RAQ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.2% | -1.2% | -0.7% |
| 1Y | 4.5% | -5.0% | -1.8% |
Return vs Industry: 0RAQ exceeded the UK Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: 0RAQ exceeded the UK Market which returned -9% over the past year.
Price Volatility
| 0RAQ volatility | |
|---|---|
| 0RAQ Average Weekly Movement | 0.3% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RAQ has not had significant price volatility in the past 3 months.
Volatility Over Time: 0RAQ's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 225 | Christoffer Lorenzen | www.karopharma.com |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.
Karo Pharma AB (publ) Fundamentals Summary
| 0RAQ fundamental statistics | |
|---|---|
| Market cap | kr16.59b |
| Earnings (TTM) | -kr189.85m |
| Revenue (TTM) | kr3.47b |
4.8x
P/S Ratio-87.4x
P/E RatioIs 0RAQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RAQ income statement (TTM) | |
|---|---|
| Revenue | kr3.47b |
| Cost of Revenue | kr1.50b |
| Gross Profit | kr1.96b |
| Other Expenses | kr2.15b |
| Earnings | -kr189.85m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 56.67% |
| Net Profit Margin | -5.48% |
| Debt/Equity Ratio | 104.8% |
How did 0RAQ perform over the long term?
See historical performance and comparison